Empirical Ventures

Empirical Ventures

Empirical Ventures was founded in 2024 and is headquartered in Bristol. The firm operates as a specialist venture capital manager and venture builder, concentrating exclusively on early-stage deep-tech and life-science companies that emerge from fundamental scientific research. Its founding thesis is that the UK produces world-class academic breakthroughs that too often stall between the lab bench and a fundable startup; the firm steps into that gap. The investment strategy spans Life Sciences, Advanced Materials, TechBio, Photonics and Quantum Hardware, Robotics and Automation, and AgTech/DeepTech. Empirical runs a venture-builder model alongside direct venture investments, targeting seed-stage companies built around entirely new technologies with strong IP defensibility. Confirmed portfolio companies include MitoRx Therapeutics (mitochondrial-protective small molecules for Duchenne muscular dystrophy and Huntington’s disease), EnsiliTech (room-temperature stabilisation of biologics to eliminate cold-chain dependence), OSSTEC (3D-printed knee implants with biomimetic fixation), MintNeuro (semiconductor technology for neural implants, spun out of Imperial College London), Anaphite (dry-coated electrode materials for solid-state batteries), and Albotherm (reversible glass coatings for passive cooling). The portfolio also includes Argonaute RNA, Halo Therapeutics, Xgenera, OutSee, BoobyBiome, Healome, Zentraxa, Silveray, Nexus Additive Materials, Transdermal Diagnostics, Muddy Machines, QV Bioelectronics, WASE, Signapse, CheMastery, and Exciting Instruments. The firm’s geographic focus is the United Kingdom, drawing heavily from research universities including Imperial College London and the University of Sheffield. The firm was established in 2024 and is building its initial portfolio. No publicly disclosed figures exist for total professionals, assets under management, or aggregate deployment. Empirical identifies itself as a venture capital manager combined with a venture builder — a structure that allows it to provide hands-on operational support to scientist-founders during company formation, a period where technical risk is acute and external capital is scarce. The firm has not disclosed the names of its founding principals or investment decision-makers publicly. Empirical Ventures’ structural edge is its dual role as both early-stage VC and active venture builder. Rather than wait for spinouts to arrive fully formed, the firm embeds with university and research-institute teams during the ideation and incorporation phase, supplying not only seed capital but the operational scaffolding — legal entity formation, initial GTM strategy, follow-on fundraising architecture — that a pure financial investor would not typically provide. That architecture makes it a formation-stage partner rather than a passive LP, a posture that is uncommon in UK deep-tech venture and that positions the firm to capture deal flow before generalist seed funds engage.